EGFR and neoplasm: Since EGFR antagonists interfere with the activation of several intracellular pathways that control cell proliferation, survival, apoptosis, metastatic capability, invasion and tumor-induced angiogenesis, it is clear that several different molecular changes could be responsible for the development of resistance to these inhibitors [16].